← Volver a la portada
Oceanía · Mercados regionales · Stockhead

Imagion Biosystems secures first site for MagSense Phase 1b/2 clinical trial

Publicado por Stockhead · Australia hace 48 min
Source: Imagion Biosystems
Source: Imagion Biosystems · Stockhead

Resumen detallado

Imagion Biosystems has secured the first clinical trial site for its Phase 1b/2 trial of lead MagSense Imaging Agent in ... Read More The post Imagion Biosystems secures first…

Imagion has achieved a key milestone towards the start of its MagSense trial in HER2+ breast cancer. Pic: Getty Images

Special Report: Imagion Biosystems has secured the first clinical trial site for its Phase 1b/2 trial of lead MagSense Imaging Agent in HER2+ breast cancer after executing a clinical trial agreement (CTA) with US-based Regis Clinical Research.

The CTA marks a key milestone toward trial initiation for Imagion Biosystems (ASX:IBX), formally committing Regis to participation as a trial site.

Miami-based Regis is an independent clinical research organisation specialising in clinical trial management, with a focus on oncology.

Its team of investigators and researchers supports study initiation, trial conduct and patient recruitment.

Following execution of the CTA, Imagion and Regis intend to progress towards site activation and patient recruitment.

“We are excited to have Regis as our first trial site under contract,” said Imagion Biosystems, Inc. president Ward Detwiler.

“As an organisation focused on efficient study execution and with deep experience across oncology trials, Regis aligns with IBX’s focus on expediently advancing our clinical development goals.”

Beyond Regis, seven sites have been selected for the trial. IBX said it was working to finalise contracts and activate the remaining sites as quickly as possible.

Inicio del artículo, extracto de Stockhead. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Stockhead Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stockhead.com.au)

También te puede interesar